Ministry of Health and Welfare Reclassifies Risk Level of Related Treatments as "Low Risk"
Treatment Plans Reviewed Based on Supporting Literature, Including Papers in SCIE-Ranked Journals

The procedures required to treat patients using cultured autologous immune cells will be simplified. Going forward, applicants will be able to apply for a treatment plan by providing sufficient supporting literature, without first conducting preliminary clinical research that can take around two to three years.


Barrier to Cultured Autologous Immune Cell Therapy Lowered... Applications Now Possible Without Preliminary Clinical Research View original image

The Ministry of Health and Welfare said on the 30th that it had issued a notice reclassifying the risk level of clinical research and treatment using cultured autologous immune cells from its previous level to "low risk."


The measure follows a review in June by the Committee for Review of Advanced Regenerative Medicine and Advanced Biological Products, which confirmed the safety of research and treatment involving cultured autologous immune cells and considered adjusting their risk level. The Enforcement Decree of the Advanced Regenerative Bio Act stipulates that the committee may review and adjust risk levels when sufficient research data and treatment cases have been accumulated to demonstrate safety.


As a result, researchers can apply for an advanced regenerative medicine treatment plan based on supporting literature, including academic papers from Korea and abroad, without conducting preliminary clinical research. However, given the specialized nature of cell culture technology and the need to ensure safety, cell collection, testing, and processing must be carried out at an existing designated cell processing facility.


Human cells used in treatment must have the same origin, characteristics, and mechanism of action as the cells used in the supporting literature. Manufacturing and quality control standards for the cells will be assessed based on materials submitted by the cell processing facility. This does not mean the cells must be biologically identical in every respect; they must conform to the generally known characteristics and specifications of the relevant cells.


Safety and efficacy will be reviewed based on the supporting literature or results from existing clinical research in advanced regenerative medicine. The proposed treatment plan must be consistent with the supporting evidence in terms of the indication (the target disease and patient group), treatment objective, and route of administration. Cell dosage and the number of administrations may be approved within a similar range, provided that there is a reasonable basis for them.


Supporting literature must consist of papers published in peer-reviewed international academic journals ranked SCIE or higher. Researchers must also submit a literature search strategy detailing the databases and search terms used, the date and number of search results, and the reasons for selecting or excluding papers. They must present clinical results from a sufficient number of patients to allow efficacy to be assessed.


Applicants may also submit additional supporting literature when applying for a treatment plan based on the results of preliminary clinical research, and the same standards for literature quality will apply. Literature from Korea and abroad may be used. The latest research should be prioritized, although older literature may also be accepted depending on the characteristics of the treatment.



Choi Gyeongil, a senior official for advanced medical support at the Ministry of Health and Welfare, said, "With the issuance of this notice, applicants can now seek approval for a treatment plan involving cultured autologous immune cells based on supporting literature, even without conducting clinical research." He added, "We will work to provide new treatment opportunities for patients with severe, rare, and intractable diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing